N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
Phase 2 N=204 Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 — -9.0; -7.4 Scores on a scale — p=0.121
N/A N=9 European Deep Brain Stimulation (DBS) Depression Study
Depressive Disorder, Major
Primary: Mean Percent Change From Baseline in MADRS Score — -7.7; -7.4; -8.8; -6.2 percentage change from baseline
Phase 3 N=598 Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of…
Phase 3 N=1,149 A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum — 63.0; 63.0 days — p=0.5100
Phase 3 N=211 Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
Phase 3 N=327 A Trial of AXS-05 in Patients With Major Depressive Disorder
Depression · Major Depressive Disorder
Primary: Change in MADRS Total Score From Baseline to Week 6 — 15.91; 12.04 score on a scale — p=0.002
Phase 4 N=53 Effects of Treatment on Decision-making in Major Depression
Major Depressive Disorder · Healthy Controls
Primary: Money Earned — 23.2; 25.0; 20.5; 21.9 US Dollars
N/A N=100 Supportive and Supportive-Expressive Treatment for Depression
Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HRSD) — 12.32; 12.06; 20.20; 20.08 units on a scale — p=.016
Phase 4 N=480 Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase — 4.1; 4.8; 5.3 scores on a scale
Phase 3 N=569 A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal — -13.9; -14.4; -12.9 Scores on a scale — p=0.853
Phase 2 N=504 MDD POC Study GSK372475 Subjects Depressive Disease
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
Phase 2 N=15 ANC-501 in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change From Baseline (Day 1) to Day 56 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. — -17.5 score on a scale
N/A N=26 Transcranial Direct Current Stimulation Therapy for Major Depression
Major Depressive Disorder
Primary: Clinical Response — 22 Participants
Phase 2 N=67 Rapid Antidepressant Effects of Ketamine in Major Depression
Depression · Mood Disorders · Major Depresssion
Primary: MADRS Score - Baseline — 1.17; 1.48; 33.83; 31.82 units on a scale
Phase 4 N=85 Advancing Personalized Antidepressant Treatment Using PET/MRI
Depression
Primary: Change From Baseline in Hamilton Depression Rating Scale at 8 Weeks — 11.81; 9.41 score on a scale
Phase 2 N=207 Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
Adjunctive Treatment of Major Depressive Disorder
Primary: Change From Baseline to Week 5 in the HAMD-17 Total Score — 22.9; 22.0; 20.3; 20.4 score on a scale — p=0.0390
Phase 2 N=20 Spinal Cord Stimulation for the Treatment of Major Depressive Disorder
Major Depressive Disorder
Primary: Montgomery Asberg Depression Rating Scale (MADRS) Score Change — -21.7; -14.6 summed total scores — p==0.040
Phase 2 N=102 A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
Major Depression
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A — 92.3 percentage of participants
Phase 3 N=513 A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
Major Depressive Disorder
Primary: Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score — -6.18; -6.25; -6.91 units on a scale — p=0.264
Phase 3 N=874 Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
Major Depressive Disorder
Primary: Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185 — 30.2; 14.3 percent estimated…
N/A N=30 Intensive tDCS for MDD: Feasibility Study
Major Depressive Disorder
Primary: Change in Depressive Symptoms Measured by the Patient Health Questionnaire (PHQ-9) — 21; 31.5 percentage of change
Phase 2 N=341 A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
Depressive Episode · Bipolar 1 Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -19.485; -19.324; -16.196 units on a scale — p=0.044
Phase 3 N=463 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -23.9; -21.6 units on a scale — p=0.193
Phase 3 N=337 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -24.3; -23.7; -24.3 units on a scale — p=0.999
Phase 3 N=488 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Bipolar Depression · Major Depressive Disorder
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.1; -12.4 score on a scale — p=<0.0001
Phase 2 N=160 An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
Depressive Disorder · Anxiety
Primary: Double-blind Treatment Period: Change From Baseline in Hamilton Depression Rating Scale (HDRS17) Total Score at Week 6 (eITT Population) — -6.1; -6.5 Units on a scale…
Phase 2 N=234 Study Of 323U66 SR In Major Depressive Disorder
Depressive Disorder
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 in Observed Cases — -16.8 Score on a scale